{
    "clinical_study": {
        "@rank": "31630", 
        "arm_group": [
            {
                "arm_group_label": "NOMAC-E2 500/300", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive NOMAC-E2 500/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days."
            }, 
            {
                "arm_group_label": "NOMAC-E2 700/300", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive NOMAC-E2 700/300 for three treatment periods,  each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days."
            }, 
            {
                "arm_group_label": "NOMAC-E2 900/300", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive NOMAC-E2 900/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days."
            }, 
            {
                "arm_group_label": "ENG-E2 75/300", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive ENG-E2 75/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days."
            }, 
            {
                "arm_group_label": "ENG-E2 100/300", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive ENG-E2 100/300 for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days."
            }, 
            {
                "arm_group_label": "ENG-E2 125/300", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive ENG-E2 125/300 for three 28-day treatment periods, each treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days."
            }, 
            {
                "arm_group_label": "NuvaRing\u00ae (ENG-EE 120/15)", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will receive NuvaRing\u00ae for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days."
            }
        ], 
        "brief_summary": {
            "textblock": "The study is designed to the evaluate ovulation inhibition, vaginal bleeding, and\n      pharmacokinetics associated with three different doses of two next generation vaginal rings\n      (NGRs), identifying at least one whose control of menstrual cycles is not inferior to that\n      of NuvaRing\u00ae."
        }, 
        "brief_title": "A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012 AM2)", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Contraception", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Uterine Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body mass index (BMI) \u226518 and \u226435\n\n          -  Regular cycles from 24 to 35 days in length, with an intraindividual\n\n        variation of \u00b13 days permitted within this range\n\n          -  Good physical and mental health\n\n        Exclusion Criteria:\n\n          -  Diabetes mellitus with vascular involvement\n\n          -  Presence of a severe or multiple risk factor(s) for venous or arterial\n\n        thrombosis\n\n          -  Severe dyslipoproteinemia\n\n          -  Severe hypertension\n\n          -  Presence or history of pancreatitis associated with severe\n\n        hypertriglyceridaemia\n\n          -  Presence or history of severe hepatic disease\n\n          -  Undiagnosed vaginal bleeding\n\n          -  Known or suspected pregnancy\n\n          -  Participation in another investigational drug study within 30 days prior to\n\n        screening visit\n\n          -  History of malignancy \u22645 years, except for adequately treated basal cell or\n\n        squamous cell skin cancer, or in situ cervical cancer\n\n          -  Documented abnormal cervical smear result  in 6 months prior to screening\n\n        visit\n\n          -  Sterilization using using a fallopian tube occlusion device (e.g., Essure\n\n        method)\n\n          -  Sex hormone therapy within 2 months prior to screening visit for purpose\n\n        other than contraception, or injectable hormonal contraception within 6\n\n        months prior to screening"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "666", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709318", 
            "org_study_id": "P06109", 
            "secondary_id": "2012-002459-41"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "NOMAC-E2 500/300", 
                    "NOMAC-E2 700/300", 
                    "NOMAC-E2 900/300"
                ], 
                "description": "Daily release of 500, 700, or 900 \u03bcg.", 
                "intervention_name": "Nomegestrol acetate (NOMAC)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ENG-E2 75/300", 
                    "ENG-E2 100/300", 
                    "ENG-E2 125/300", 
                    "NuvaRing\u00ae (ENG-EE 120/15)"
                ], 
                "description": "Daily release of 75, 100, or 125 \u03bcg", 
                "intervention_name": "Etonogestrel (ENG)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NuvaRing\u00ae (ENG-EE 120/15)", 
                "description": "Daily release of 15 \u03bcg", 
                "intervention_name": "Ethinyl estradiol (EE)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "NOMAC-E2 500/300", 
                    "NOMAC-E2 700/300", 
                    "NOMAC-E2 900/300", 
                    "ENG-E2 75/300", 
                    "ENG-E2 100/300", 
                    "ENG-E2 125/300"
                ], 
                "description": "Daily release of 300 \u03bcg", 
                "intervention_name": "Estradiol (E2)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Ethinyl Estradiol", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate", 
                "3-keto-desogestrel", 
                "Megestrol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 7, 2013", 
        "number_of_arms": "7", 
        "official_title": "A Multicenter, Randomized, Partially-blinded, Phase IIb Dose-finding Study on Ovarian Function, Vaginal Bleeding Pattern, and Pharmacokinetics Associated With the Use of Combined Vaginal Rings Releasing 17\u03b2-estradiol Plus Three Different Doses of Either Nomegestrol Acetate or Etonogestrel in Healthy Women Aged 18-35 Years. Protocol MK-8175A/MK-8342B 012", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of Progesterone Concentrations >16 nmol/L", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Treatment Cycle 1 through Day 28 of Treatment Cycle 3 (Study Days 1-84)"
            }, 
            {
                "measure": "Incidence of Break-through Bleeding and/Or Spotting (BTB-S) During Cycle 3", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 3 through Day 28 of Cycle 3 (Study Days 57-84)"
            }
        ], 
        "removed_countries": {
            "country": [
                "Denmark", 
                "Germany", 
                "Hungary", 
                "Netherlands", 
                "Norway", 
                "Poland", 
                "Spain"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709318"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of Withdrawal Bleeding-spotting During Cycle 2", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 2 through Day 28 of Cycle 2 (Study Days 29-56)"
            }, 
            {
                "measure": "Intensity of Withdrawal Bleeding During Cycle 2 (Defined as the Ratio of Number of Withdrawal Bleeding Days/Number of Withdrawal Bleeding And/Or Spotting Days)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 2 through Day 28 of Cycle 2 (Study Days 29-57)"
            }, 
            {
                "measure": "Intensity of BTB-S during Cycle 3 (Defined as the Ratio of the Number of Breakthrough Bleeding Days/Number of  BTB-S days)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 3 through Day 28 of Cycle 3 (Study Days 57-84)"
            }, 
            {
                "measure": "Number of Participants With Venous or Arterial Thrombotic/Thrombolic Events", 
                "safety_issue": "Yes", 
                "time_frame": "From Cycle 1, Day 1 up to 8 days after Day 28 of Cycle 3 (Study Days 1 through 91)"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}